Table A1.
Interaction effects.
| Feature Interactions | p-Value of Effect | ||
|---|---|---|---|
| Longitudinal Remission | Durability | ||
| Numeric Values Used for Several Features | All Features Discretized, Except for “Days since Start of UST Treatment” | ||
| (Baseline hemoglobin) × (Sex) | 0.626 | N/A | 0.821 |
| (HBI at the first UST dose, categorized) × (Baseline fecal calprotectin) | <0.05 | N/A | 0.307 |
| (HBI at the first UST dose, categorized) × (Baseline albumin) | <0.05 | N/A | 0.239 |
| (HBI at the first UST dose, categorized) × (Baseline hemoglobin) | <0.05 | N/A | 0.306 |
| (HBI at the first UST dose, categorized) × (Baseline CRP) | <0.05 | N/A | <0.05 |
| (Days since the start of UST treatment) × (Years between diagnosis and start of UST) | <0.05 | N/A | N/A |
| (Days since the start of UST treatment) × (BMI) | <0.05 | N/A | N/A |